Radiopharmaceuticals: all 1,299 studies that test it

Page 4 of 13. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.

• Study of [18F]FAPI-74 PET in Patients With Gastrointestinal CancersCompletedNCT05641896Phase 2Results posted
• 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate CancerCompletedNCT05547386Phase 3Results posted
• Feasibility of [11C]Acetate-PET in LAM and TSCActive, not recruitingNCT05467397Phase 1/2Results posted
• 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)CompletedNCT05407311Phase 2Results posted
• Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal CarcinomaCompletedNCT05262855Phase 2Results posted
• 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)CompletedNCT05249127Phase 1/2Results posted
• Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RATerminatedNCT05246280Phase 3Results posted
• A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic AmyloidosisCompletedNCT05235269Phase 2Results posted
• 68Ga PSMA PET Imaging for the Treatment of Advanced Liver CancerCompletedNCT05176223Phase 2Results posted
• GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2TerminatedNCT05130255Phase 1Results posted
• Rose Bengal Electromagnetic Activation With Green Light for Infection ReductionCompletedNCT05110001Phase 3Results posted
• PET Imaging of Cyclooxygenase in Multiple SclerosisTerminatedNCT05062083Phase 2Results posted
• 18F-DCFPyL PET/CT in Hepatocellular CarcinomaTerminatedNCT05009979Phase 2Results posted
• Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m TilmanoceptCompletedNCT04947137Phase 2Results posted
• 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor ExpressionTerminatedNCT04927663Phase 1Results posted
• Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBCCompletedNCT04897763Early Phase 1Results posted
• 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver CancerCompletedNCT04762888Phase 2Results posted
• Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast CancerCompletedNCT04758780Phase 2Results posted
• Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast CancerCompletedNCT04750473Phase 1Results posted
• 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate CancerTerminatedNCT04727736Phase 2Results posted
• 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate CancerTerminatedNCT04716725Phase 2Results posted
• Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance ImagingTerminatedNCT04698564Phase 2Results posted
• Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted TherapyActive, not recruitingNCT04692103Phase 2Results posted
• 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerActive, not recruitingNCT04689828Phase 3Results posted
• 68 Ga-PSMA for High Risk Prostate CancerCompletedNCT04614363Phase 1/2Results posted
• Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal AdenocarcinomaTerminatedNCT04565327Phase 2Results posted
• Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial CancerTerminatedNCT04511026Phase 2Results posted
• Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired SubjectsCompletedNCT04474405Early Phase 1Results posted
• Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's DiseaseCompletedNCT04468347Phase 1Results posted
• Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)CompletedNCT04410367Phase 2Results posted
• Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain MetastasesCompletedNCT04410133Phase 3Results posted
• 18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate CancerCompletedNCT04390880Phase 2Results posted
• Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRICompletedNCT04382911Phase 2Results posted
• 18F-FTC-146 PET/CT in Newly-Diagnosed OsteosarcomaTerminatedNCT04365660Phase 2Results posted
• HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate CancerTerminatedNCT04264208Phase 2Results posted
• Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine TumorsActive, not recruitingNCT04234568Phase 1Results posted
• Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck CancerTerminatedNCT04217057Phase 1Results posted
• Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer RecurrenceCompletedNCT04186845Phase 3Results posted
• Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.CompletedNCT04186819Phase 3Results posted
• The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate CancerCompletedNCT04179968Phase 2Results posted
• PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot StudyTerminatedNCT04176497Phase 2Results posted
• 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory MedulloblastomaTerminatedNCT04167618Phase 1/2Results posted
• 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging TherapiesCompletedNCT04158245Phase 2Results posted
• An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate CancerTerminatedNCT04134208Phase 4Results posted
• CLR 131 Combined With Radiation for Head and Neck CancerCompletedNCT04105543Phase 1Results posted
• Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RATerminatedNCT04078191Phase 2Results posted
• PET Fibrin Imaging of DVT and PETerminatedNCT04022915Phase 1Results posted
• Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone MetastasesTerminatedNCT03996473Phase 1Results posted
• Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate CancerCompletedNCT03995888Phase 1Results posted
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced CancerCompletedNCT03991494Phase 1Results posted
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETActive, not recruitingNCT03972488Phase 3Results posted
• PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) RadioligandTerminatedNCT03958630Phase 1Results posted
• 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU TherapyCompletedNCT03949517Phase 1/2Results posted
• Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar ImagingCompletedNCT03938636Phase 2Results posted
• Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's DiseaseCompletedNCT03901105Phase 3Results posted
• A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan InterpretationCompletedNCT03901092Phase 3Results posted
• 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast CancerCompletedNCT03831711Phase 1/2Results posted
• 18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung NodulesCompletedNCT03824535Phase 2Results posted
• 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate CancerCompletedNCT03809078Phase 2Results posted
• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT03805594Phase 1Results posted
• Gallium-68 PSMA-11 PET Imaging in Prostate Cancer PatientsCompletedNCT03803475Phase 3Results posted
• 18F-Fluorocholine for the Detection of Parathyroid AdenomasCompletedNCT03764007Phase 2/3Results posted
• Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer OutcomesActive, not recruitingNCT03762759Phase 2Results posted
• Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate CancerCompletedNCT03739684Phase 3Results posted
• Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the BoneCompletedNCT03707184Phase 2Results posted
• Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate CancerCompletedNCT03698370Phase 2Results posted
• Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate CancerTerminatedNCT03689582Phase 2Results posted
• PSMA Imaging of Localized Prostate CancerCompletedNCT03675451Phase 2Results posted
• Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATECompletedNCT03673943Phase 3Results posted
• 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPCTerminatedNCT03545165Phase 1/2Results posted
• Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.TerminatedNCT03525392Phase 1Results posted
• Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate CancerCompletedNCT03511664Phase 3Results posted
• Tau Screening Study in Subjects With Early Symptomatic ADCompletedNCT03467477Phase 2Results posted
• Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid CancerTerminatedNCT03463889Phase 2Results posted
• Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain MetastasesCompletedNCT03463525Phase 1Results posted
• Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03448458Phase 2Results posted
• Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.TerminatedNCT03423082Phase 4Results posted
• Gallium-68 PSMA-11 PET in Patients With Biochemical RecurrenceCompletedNCT03396874Phase 2Results posted
• Imaging Tau in Alzheimer's Disease and Normal AgingCompletedNCT03373604Phase 2Results posted
• Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical RecurrenceCompletedNCT03353740Phase 3Results posted
• Tau Screening Study in Patients With Early Symptomatic ADCompletedNCT03322462Phase 2Results posted
• Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic AdenocarcinomaCompletedNCT03318497Phase 2Results posted
• Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to BoneCompletedNCT03304418Phase 2Results posted
• Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) ImagingTerminatedNCT03303469Phase 2Results posted
• Phase I Trial of 225Ac-J591 in Patients With mCRPCCompletedNCT03276572Phase 1Results posted
• 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesTerminatedNCT03275402Phase 2/3Results posted
• High Resolution PET-MRI Before Prostate Cancer HIFUCompletedNCT03263780Phase 2Results posted
• The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade GliomaCompletedNCT03242824Phase 2Results posted
• Diagnostic Imaging for Clear Cell Renal Cell CarcinomaTerminatedNCT03185182Phase 2Results posted
• An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)CompletedNCT03157167Phase 1Results posted
• Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT ScanCompletedNCT03136328Phase 3Results posted
• 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate CancerCompletedNCT03113617Phase 2Results posted
• 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or InflammationTerminatedNCT03103490Phase 2Results posted
• 99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) PatientsTerminatedNCT03065218Phase 4Results posted
• Flortaucipir 18F PET Imaging in BIOCARD StudyTerminatedNCT03052972Phase 1Results posted
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsActive, not recruitingNCT03049189Phase 3Results posted
• Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPCCompletedNCT03042468Phase 1/2Results posted
• Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapyTerminatedNCT03042312Phase 2Results posted
• Flortaucipir PET Imaging in Subjects With FTDCompletedNCT03040713Phase 1Results posted
• The Role of F-18 Florbetapir in the Early Detection of Cardiac AmyloidosisTerminatedNCT03040427Phase 4Results posted

← Radiopharmaceuticals overview